Several clinical trials involving mutIDH inhibitors and DNMT inhibitors in AML are ongoing; early data was presented at the 2018 ASCO Annual Meeting from a phase 1b/2 study of combination treatment in adults with newly diagnosed IDH-mutant AML testing both Ivosidenib and Enasidenib in combination with azacitidine (ClinicalTrials.gov NCT02677922) (94). This evidence concerns the gene IDH2 and acute myeloid leukemia.